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Abstract 
Nostoc commune var. sphaeroides Kützing (N. commune), a blue-green alga, has been used as both a 
food ingredient and in medicine for centuries. To determine the effect of N. commune on cholesterol 
metabolism, N. commune lipid extract was incubated at increasing concentrations (25–100 mg/L) with 
HepG2 cells, a human hepatoma cell line. The addition of N. commune lipid extract markedly reduced 
mRNA abundance of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) and LDL receptor 
(LDLR) (P < 0.05), with a concomitant decrease in their protein expression (P < 0.001). Reduced 
HMGR activity by 90% with N. commune lipid extract confirmed the inhibitory role of N. commune in 
cholesterol synthesis (P < 0.006). To elucidate a molecular mechanism underlying the repression of 
HMGR and LDLR by N. commune lipid extract, expression of sterol regulatory element binding pro-
tein 2 (SREBP-2) was assessed. Whereas mRNA for SREBP-2 remained unchanged, SREBP-2 mature 
protein was reduced by N. commune (P < 0.009). In addition, N. commune lipid extract also decreased 
SREBP-1 mature protein by ~30% (P < 0.002) and reduced the expression of SREBP-1-responsive 
genes such as fatty acid synthase and stearoyl CoA desaturase 1 (SCD-1) (P < 0.05). Therefore, our 
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results demonstrate that N. commune lipid extract inhibits the maturation process of both SREBP-1 
and -2, resulting in a decrease in expression of genes involved in cholesterol and fatty acid metabo-
lism. 
 
Abbreviations: BGA, blue-green algae; CHD, coronary heart disease; Ct, threshold cycle; FAS, fatty 
acid synthase; HMGR, 3-hydroxy-3-methylglutaryl-Coenzyme A reductase; INSIG, insulin-induced 
gene; LDLR, LDL receptor; SCAP, SREBP cleavage-activating protein; SCD-1, stearoyl CoA desatu-




Coronary heart diseases (CHD) are the leading cause of death in the United States and 
other Westernized countries. A direct correlation exists between the concentration of 
plasma cholesterol and the severity of atherosclerosis (1). According to the 2001 report of 
the National Cholesterol Education Program, an expert panel estimated that 65 million US 
adults should be recommended to have therapeutic lifestyle changes, including diet, and 
36 million of that population also need drug therapy for treatment of elevated cholesterol 
levels (2). Currently, statin drugs are widely prescribed to lower plasma cholesterol con-
centration. Statins primarily reduce plasma cholesterol levels by inhibiting 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGR), the rate-limiting enzyme in the cholesterol bio-
synthetic pathway. Although statins have proven to be effective at lowering plasma cho-
lesterol level, potential adverse effects may occur (1,3). 
Increased public interest in natural and herbal medicine has prompted the identification 
of natural products with heart protection. Several herbal and functional food supplements 
have been used for primary prevention of heart disease. Consumption of garlic (4), soy 
protein (5), and artichoke (6) has been reported to moderately decrease plasma cholesterol 
levels. In addition, soluble fibers from barley, beans, oat bran, and psyllium reduced 
plasma cholesterol concentration when consumed by healthy hyperlipidemic patients on 
a low-fat diet (7). To meet the public’s demand for natural foods for the prevention of CHD, 
continuous efforts need to be made to discover and develop new bioactive natural prod-
ucts. 
Blue-green algae (BGA) are among the most primitive life forms on earth (8). Edible 
BGA, such as Spirulina and Aphanizomenon flos-aquae, are currently marketed as dietary 
supplements with various health claims for immune function, inflammation, and heart 
disease. Spirulina is known to be rich in vitamins, minerals, essential and nonessential 
amino acids, trace elements, and essential fatty acids (9). Currently, Spirulina is harvested 
from controlled ponds in dozens of countries and is being sold as an organic dietary sup-
plement. In contrast to Spirulina, most of A. flos-aquae products are naturally harvested 
from the Upper Klamath Lake in southern Oregon and therefore it is called “a natural di-
etary supplement.” Although the term “natural” could attract consumers, concerns over 
naturally grown BGA have been raised because they are easily contaminated with Micro-
cystis aeruginosa, which generates potent hepatotoxin microcystins, as well as with heavy 
metals (10). In response to this concern, Health Canada performed broad sampling of BGA 
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supplements available on the Canadian market in May 1999 to test their microcystin con-
tents. The survey revealed that only Spirulina has no detection of microcystins and many 
non-Spirulina BGA products harvested from natural lakes contain microcystins above lev-
els considered acceptable by Health Canada and WHO. In addition, the quality of naturally 
grown BGA can vary depending on their growing environments, e.g., altitude, tempera-
ture, and sun exposure (11). 
Nostoc commune var. sphaeroides Kützing (N. commune) is an edible BGA that has been 
used as a food delicacy as well as an herbal medicine in countries to which it is native for 
thousands of years. It has been historically suggested that N. commune can treat a variety 
of medical conditions, including inflammation, night blindness, burns, anxiety, and chronic 
fatigue. Studies have also demonstrated various health benefits from N. commune, includ-
ing antiviral and anticancer activities (12–14). Importantly, a cholesterol-lowering effect of 
N. commune was reported in rats fed a high-cholesterol diet, and the effect was attributed 
to its high-fiber content (15). 
Although previous research has shown N. commune confers health benefits, the investi-
gation into the mechanisms behind the biological effects have been limited. In this study, 
we investigated the ability of N. commune lipid extract to influence key regulators of both 
cholesterol and fatty acid metabolism in HepG2 cells, a human hepatoma cell line. Because 
sterol regulatory element binding proteins (SREBP) are transcriptional factors that play a 
central role in regulating both cholesterol and fatty acid metabolism (11,16), the effect of 




Preparation of Nostoc lipid extract 
Fresh N. commune was obtained from Algaen Corporation. N. commune was lyophilized 
and ground for lipid extraction by the Bligh-Dyer method (17). Briefly, 42 mL of chloro-
form:methanol (1:2, v:v) was added to ~3 g of dry N. commune and vortexed. After the 
addition of 14 mL of chloroform, the sample was vortexed and filtered to remove solids. 
Subsequently, 6.3 mL of 0.05% H2SO4 was added and vortexed. To separate phases, the 
sample was centrifuged at 500 × g; 5 min and the lower liquid phase was recovered. Tubes 
containing lipid extract in chloroform were purged with N2 and tightly sealed. The lipid 
extract was stored at –80°C with the oxygen absorber AGELESS (Mitsubishi Gas Chemical 
America) to prevent oxidation until use. To incorporate the lipid extract into cell culture 
medium, chloroform was evaporated under nitrogen and cell culture medium was added 
for subsequent sonication at room temperature for 5 min. 
 
Cell culture 
HepG2 cells (ATCC) were maintained in minimal essential medium containing 10% fetal 
bovine serum, 100 kU/L penicillin, 100 mg/L streptomycin, 1× vitamins, and 2 mmol/L L-
glutamine in a humidified chamber at 37°C with 5% CO2. All cell culture supplies were 
purchased from MediaTech. Cells were plated at a density of 3 × 105 cells per well in 12-
well plates. When cells reached ~90% confluence, N. commune lipid extract (0–100 mg/L) 
was added to culture medium for 24 h. 
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Cytotoxicity measurement 
Cytotoxicity of N. commune lipid extract was determined using Cell Counting Kit-8 (Dojindo 
Molecular Technologies) according to the manufacturer’s instructions. SDS (0.5 mmol/L) 
was also added as a positive control for cytotoxicity. Data are expressed as cell viability 
(%) relative to a control that was not incubated with N. commune lipid extract. 
 
Total RNA isolation and quantitative real-time PCR 
HepG2 cells were washed twice with cold PBS and 1 mL of TRIZOL reagent (Invitrogen) 
was added to each well of 12-well plates for total RNA isolation following the manufac-
turer’s protocol. One microgram of total RNA was treated with DNase I (Promega) to re-
move any genomic DNA. The RNA samples were reverse transcribed by Moloney murine 
leukemia virus reverse transcriptase (Promega) for subsequent real-time PCR analysis us-
ing the Sybr Green procedure and an ABI 7300 instrument (Applied Biosystems). Primers 
for HMGR, LDL receptor (LDLR), fatty acid synthase (FAS), stearoyl CoA desaturase 1 
(SCD-1), SREBP-1c, SREBP-2, and glyceraldehyde 3-phosphate dehydrogenase were de-
signed according to GenBank database using the Primer Express software provided by 
ABI. Primer sequences are given in Table 1. Expression of mRNA values was calculated 
using the threshold cycle (Ct) value, i.e. the number of PCR cycles at which the fluorescent 
signal during the PCR reaches a fixed threshold. For each sample, ΔCt, sample was calculated 
by subtracting the Ct value of glyceraldehyde 3-phosphate dehydrogenase, a house-keep-
ing gene, from that of the gene of interest to normalize the data. The expression levels 
relative to control were estimated by calculating ΔΔCt (ΔCt, sample – ΔCt, control) and subse-
quently using the 2–ΔΔCt method (18). 
 
Table 1. Quantitative Realtime PCR primers 
Gene Forward Primer Reverse Primer 
HMGR 5′-CCCAGTTGTGCGTCTTCCA-3′ 5′-TTCGAGCCAGGCTTTCACTT-3′ 
LDLR 5′-ACTGGGTTGACTCCAAACTTCAC-3′ 5′-GGTTGCCCCCGTTGACA-3′ 
SREBP-2 5′-TCCGCCTGTTCCGATGTAC-3′ 5′-TGCACATTCAGCCAGGTTCA-3′ 
SREBP-1c 5′-TCAGCGAGGCGGCTTTGGAGCAG-3′ 5′-CATGTCTTCGATGTCGGTCAG-3′ 
FAS 5′-CGCTCGGCATGGCTATCT-3′ 5′-CTCGTTGAAGAACGCATCCA-3′ 
SCD-1 5′-CCGACGTGGCTTTTTCTTCT-3′ 5′–TGGGTGTTTGCGCACAAG-3′ 
GAPDH 5′-GGTGGTCTCCTCTGACTTCAACA-3′ 5′-GTTGCTGTAGCCAAATTCGTTGT-3′ 
 
Western blot analysis 
HepG2 cells were incubated with 100 mg/L N. commune lipid extract for 24 h. After remov-
ing cell culture medium, cells were washed twice with cold PBS and scraped in 1 mL of 
PBS. Cells were transferred into a 1.5-mL microfuge tube and centrifuged at 12,000 × g; 5 
min at 4°C. The supernatant was removed and 25 mL of cell lysis buffer (150 mmol/L NaCl, 
25 mmol/L Tris-HCl, pH 7.4, 1% Triton X-100) containing Protease Inhibitor Cocktail set III 
(Calbiochem) was added to the cell pellet. The cells were resuspended and incubated on 
ice for 20 min, after which the cell lysates were centrifuged at 12,000 × g; 5 min at 4°C. We 
collected the supernatant and measured protein concentration by BCA assay (Pierce) using 
bovine serum albumin as a standard. 
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Fifty micrograms of cell protein was subjected to 4–16% SDS-PAGE for Western blot 
analysis using antibodies for HMGR (Upstate), LDLR (Abcam), SREBP-1 (Santa Cruz), 
SREBP-2 (Santa Cruz), and β-actin (Sigma). The blots were developed using a horseradish 
peroxidase system (Pierce) and densitometry analysis was performed using a Chemidoc 
XRS (Biorad) and Quantity One software (Biorad). β-Actin was used as a loading control 
to normalize the data. 
 
HMGR activity measurement 
HMGR activity was measured according to the methods by Brown et al. (19,20) with mod-
ification. Cell lysate was prepared as described above after 24 h incubation in the absence 
(control) or presence of N. commune lipid extract (100 mg/L). Two hundred microliters of 
reaction mixture was prepared as follows: 100 mg cellular protein, 0.1 mol/L potassium 
phosphate buffer (pH 7.5), 20 mmol/L glucose-6-phosphate, 2.5 mmol/L NADP+, 1 U glu-
cose-6-phosphate dehydrogenase, 5 mmol/L dithiothreitol, and 6 nmol [14C]HMG-CoA. 
The reaction was initiated with the addition of [14C]HMG-CoA, and the mixture was incu-
bated for 2 h at 37°C. The reaction was stopped by the addition of 20 μL of 5 mol/L HCl on 
ice. Subsequently, 0.2 μCi of [3H]mevalonolactone was added as an internal standard for 
correct recovery and incubated at 37°C for 30 min to ensure lactonization of mevalonate. 
The mevalonolactone was extracted into 5 mL of diethyl ether twice and isolated by TLC 
with acetone:benzene (1:1). Mevalonolactone was identified by comigration with a 
mevalonolactone standard and visualized by iodine vapor. Liquid scintillation counting 
was performed to measure 14C and 3H counts for mevalonolactone formation and for cor-
rection of recovery, respectively. HMGR activity was expressed as pmol mevalonate syn-
thesized ⋅ mg protein–1 ⋅ min–1. 
 
Statistical analysis 
ANOVA and Tukey’s pairwise comparison or unpaired t-test with Welch’s correction for 
unequal variance when appropriate were used to identify significant differences of treat-
ments, with P < 0.05 considered significant by GraphPad InStat 3 (GraphPad Software). 




Cytotoxicity of N. commune lipid extract in HepG2 cells 
Cytotoxicity of N. commune lipid extract was assessed by incubating HepG2 cells with in-
creasing concentrations of lipid extract for 24 h and subsequently measuring cell viability. 
Cells incubated with 25–100 mg/L of N. commune lipid extract showed no reduction in cell 
viability compared with control (data not shown). Although the percentage of viable cells 
was lowered at 200 mg/L of N. commune lipid extract (P < 0.05) compared with control, 
> 80% of cells were still viable. Because there were no decreases in cell viability in incuba-
tions with N. commune lipid extract concentrations of up to 100 mg/L, these concentrations 
were used for the cell culture experiments. 
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Effect of N. commune lipid extract on the expression of HMGR and LDLR 
Quantitative real-time PCR analysis demonstrated that N. commune lipid extract signifi-
cantly reduced mRNA abundance of HMGR and LDLR in HepG2 cells (Fig. 1A). Protein 
levels of HMGR and LDLR were measured after incubation with 100 mg/L of N. commune 
lipid extract for 24 h. Western blot analysis revealed that both HMGR and LDLR protein 
levels were significantly diminished by the addition of N. commune lipid extract by ~70% 
and ~60%, respectively (Fig. 1B). The inhibitory effect of N. commune lipid extract on 
HMGR was further confirmed by reduced HMGR activity by ~90% compared with control 
(Fig. 2). This result indicates a potential reduction in cholesterol biosynthesis by N. com-




Figure 1. N. commune lipid extract reduces mRNA and protein expression of genes in-
volved in cholesterol metabolism in HepG2 cells. (A) Real-time PCR analysis for mRNA 
expression of HMGR and LDLR in HepG2 cells incubated with N. commune lipid extract 
(0–100 mg/L) for 24 h. Data are expressed as percentage of control that was not treated 
with N. commune lipid extract (0 mg/L). Values are means ± SEM, n = 6. Means without a 
common letter differ, P < 0.05. (B) Western blot analysis for HMGR and LDLR protein 
levels in HepG2 cells incubated with 100 mg/L N. commune lipid extract for 24 h. Data are 
expressed as arbitrary units. Values are means ± SEM, n = 6. *Different from control, P < 0.005 
for HMGR, P = 0.0014 for LDLR. 




Figure 2. N. commune lipid extract reduces HMGR activity in HepG2 cells. HepG2 cells 
were incubated in the absence (control) or presence of N. commune lipid extract (100 mg/L) 
for 24 h and cell lysates were used for HMGR activity. Data are expressed as pmol meva-
lonate synthesized ⋅ mg protein–1 ⋅ min–1. Values are means ± SEM, n = 6. *Different from 
control, P = 0.02. 
 
Inhibition of SREBP maturation by N. commune lipid extract 
To determine the molecular mechanisms underlying the inhibition of HMGR and LDLR 
expression by N. commune lipid extract, we evaluated the modulation of SREBP-2 by N. 
commune. At 25–100 mg/L, N. commune lipid extract did not affect SREBP-2 mRNA abun-
dance (data not shown). Because transcriptional activity of SREBP is largely regulated by 
the maturation process of precursor proteins (21),Western blot analysis was performed to 
determine the level of mature SREBP-2 protein. At 100 mg/L, N. commune lipid extract re-
duced SREBP-2 mature protein levels by 35% (P = 0.02) (Fig. 3). Our next question was 
whether N. commune lipid extract specifically targets the SREBP-2 pathway or if SREBP-1 
could also be inhibited by N. commune lipid extract. To address this question, expression 
and maturation of SREBP-1 as well as mRNA levels of SREBP-1-responsive genes were 
measured. Similar to SREBP-2, mRNA level of SREBP-1c was not significantly changed by 
incubation with N. commune lipid extract (data not shown). However, the SREBP-1 mature 
protein level was significantly reduced by ~30% (Fig. 4A). From 25–100 mg/L of N. com-
mune lipid extract, both FAS and SCD-1 mRNA levels were significantly decreased (Fig. 
4B), indicating that N. commune lipid extract represses the expression of genes involved in 
fatty acid biosynthetic pathways through the inhibition of SREBP-1 maturation. These data 
combined indicate that N. commune lipid extract can widely affect the expression of genes 
involved in cholesterol and fatty acid metabolism by inhibiting the maturation process of 




Figure 3. N. commune lipid extract reduces mature protein levels of SREBP-2 in HepG2 
cells. HepG2 cells were incubated with 100 mg/L N. commune lipid extract for 24 h, after 
which Western blot analysis for mature SREBP-2 was performed. A representative blot of 
2 separate experiments is shown. 




Figure 4. N. commune lipid extract reduces mature protein levels of SREBP-1 and the ex-
pression of SREBP-1-responsive genes in HepG2 cells. (A) Western blot analysis for 
SREBP-1 in HepG2 cells incubated with 100 mg/L N. commune lipid extract for 24 h. The 
upper panel shows a representative blot of 3 separate experiments and the lower panel is 
densitometry analysis of the blots. Data are express as arbitrary units. Values are means 
± SEM, n = 9. *Different from control, P = 0.003. (B) Real-time PCR analysis of SREBP-1-
responsive genes in HepG2 cells incubated with 0–100 mg/L N. commune lipid extract for 
24 h. Data are expressed as percentage of control that was not treated with N. commune 
lipid extract. Bars without a common letter differ, P < 0.05. Values are means ± SEM, n = 




Consumption of foods with bioactive compounds that may confer a beneficial effect on 
health is increasingly popular. Although N. commune has been consumed for centuries for 
its purported health benefits, not all claims have been substantiated. In this study, we in-
vestigated the effect of N. commune lipid extract on the expression and function of key reg-
ulatory proteins involved in cholesterol and fatty acid metabolism in HepG2 cells. Our 
results demonstrate for the first time, to our knowledge, that N. commune lipid extract re-
presses the expression of both cholesterol and fatty acid biosynthetic genes by inhibiting 
the maturation process of SREBP-1 and -2. 
SREBP are key transcriptional regulators in cholesterol and fatty acid metabolism. They 
were first discovered as specific transcription factors that bind to the 10-base pair sterol 
regulatory element within the promoter of the gene encoding LDLR (22,23). When cellular 
cholesterol is depleted, SREBP are activated to increase the transcription of genes involved 
in the cholesterol biosynthetic pathway, including HMGR, HMG-CoA synthase, farnesyl 
diphosphate synthase, and squalene synthase (24–26). Enzymes involved in fatty acid syn-
thesis and uptake, such as acetyl-CoA carboxylase, FAS, SCD-1, and lipoprotein lipase, are 
also under the transcriptional regulation of SREBP (27–31). Later studies using cell lines 
and transgenic animals revealed that 2 isoforms of SREBP, i.e., SREBP-1 and SREBP-2, have 
different functions. SREBP-1 plays an important role in fatty acid metabolism, whereas 
SREBP-2 plays a greater regulatory role in cholesterol metabolism than fatty acid metabo-
lism (32–35). SREBP are primarily regulated at the posttranscriptional level and 2 major 
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regulatory proteins are involved in the activation of SREBP, i.e., insulin-induced genes 
(INSIG) and SREBP cleavage-activating protein (SCAP). SCAP/SREBP precursor complex 
is retained in the endoplasmic reticulum membrane via sterol-induced interaction of SCAP 
with INSIG (36,37). Upon the signal for low cellular cholesterol level, SCAP is released 
from INSIG and guides SREBP to the Golgi where a mature form of SREBP is released 
through 2-step proteolytic cleavages by site-1-protease (S1P) and site-2-protease (S2P) (38). 
The mature SREBP enters the nucleus and enhances the expression of genes involved in 
cholesterol and fatty acid metabolism. Therefore, alterations in the SREBP maturation pro-
cess could have a wide range of effects on body lipid metabolism. It needs to be further 
determined which regulatory proteins participating in the maturation process of SREBP 
are targeted by N. commune lipid extract. Nonetheless, our observation that N. commune 
lipid extract did inhibit SREBP maturation implicates its potential as a functional food to 
reduce lipogenesis as well as cholesterol biosynthesis. 
HMGR is the key rate-limiting enzyme in cholesterol synthesis. Repression of HMGR 
by competitive inhibitors such as statins in humans and by inhibition of the regulatory 
transcription factor SREBP-2 in rats has been shown to decrease the plasma cholesterol 
level (39,40). This study shows that N. commune lipid extract reduces HMGR mRNA, pro-
tein, and activity by inhibiting the maturation process of SREBP-2. N. commune lipid extract 
also significantly reduced LDLR mRNA and protein levels. LDLR is responsible for the 
uptake of LDL from circulation and decreased LDLR expression is associated with in-
creased plasma LDL cholesterol concentration (41). Therefore, N. commune lipid extract 
may not induce a favorable change in plasma total cholesterol concentration due to re-
duced LDLR expression despite its effect on decreased cholesterol biosynthesis. Alterna-
tively, depending on the body’s cholesterol status, inhibition of cholesterol biosynthesis by 
N. commune lipid extract could be enough to lower the plasma total cholesterol level. How-
ever, evidence exists showing that inhibition of SREBP-2 pathway with diminished expres-
sion of both HMGR and LDLR decreases plasma total cholesterol level. When the 
abundance of nuclear SREBP-2 was reduced in rats, which resulted in diminished mRNA 
abundance of HMGR and LDLR, plasma total cholesterol concentration as well as liver 
cholesterol content decreased (40). In addition, inhibition of SREBP maturation by knock-
ing down S1P in mice induced reductions in SREBP expression, cholesterol, and fatty acid 
biosynthesis as well as plasma cholesterol concentration (42). These studies suggest that 
the SREBP-2 maturation pathway can be a therapeutic target to lower plasma cholesterol 
level. In addition to its role in regulating cholesterol metabolism through SREBP-2, N. com-
mune lipid extract inhibited key enzymes in fatty acid biosynthetic pathways, such as FAS 
and SCD-1, through repressed maturation of SREBP-1 in HepG2 cells. Therefore, our re-
sults strongly suggest that N. commune lipid extract contains bioactive compounds that can 
inhibit the SREBP maturation process. A study is underway in our laboratory to determine 
bioactive compounds responsible for the repressed SREBP pathway in N. commune lipid 
extract. 
Atherosclerosis is a progressive and continuous process throughout life and its progres-
sion can be accelerated by dyslipidemia, including high plasma total cholesterol and tri-
glyceride concentrations. Despite extensive efforts to reduce the risk of CHD for the last 
several decades, CHD remain as the leading cause of death in the United States. Given that 
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the public’s interest in the prevention and/or therapy for CHD has shifted from the use of 
drugs to that of natural products, discovery and development of natural sources bearing 
atheroprotective properties are needed. Our current study indicates that N. commune lipid 
extract contains bioactive compounds that can decrease the expression and function of key 
regulatory genes involved in cholesterol and fatty acid biosynthetic pathways through the 
repression of the SREBP maturation process. This property of N. commune lipid extract 
could contribute to lower plasma total cholesterol as well as triglyceride concentrations. 
Although further studies are required to ensure the biological functions of N. commune, 
particularly in vivo, this study suggests a strong potential of N. commune to be developed 
as a new natural food to reduce the risk of CHD. 
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